Comparison of efficacy and safety between bovine lung lavage surfactant (Alveofact) and bovine minced lung extract surfactant (Survanta) in the Treatment Of Respiratory distress syndrome (RDS) in preterm infants â?? a Randomized clinical trial - CASTOR

Department of Neonatology0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•Preterm neonates of 28 to 34 completed weeksâ?? gestation age, with clinical features of RDS developing within 6 hours of birth and fulfilling the criteria to receive surfactant therapy within 24 hour of birth. The criteria for initial dose of Surfactant Replacement Therapy (SRT) will be: FiO2 requirement 30% or higher while on continuous positive airway pressure (CPAP) with PEEP of 6 mm Hg to maintain oxygen saturation between 90 and 94%

•1) Infants who require mechanical ventilation or intubation in the delivery room or before the initial surfactant dose.
•2) Use of surfactant prior to study entry.
•3) Significant perinatal asphyxia defined as 5 min Apgar score of < 4 or need for chest compressions during resuscitation or metabolic acidosis (pH < 7.0) in umbilical arterial blood gas or arterial blood gas obtained within 1 hour of life.
•4) Major life threatening congenital anomalies or anomalies interfering with lung development or function.
•5) Patients, whose parents or legal representative not giving consent for the s

发起方

Department of Neonatology